DEHP

B. Braun Launches Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL)

Retrieved on: 
Tuesday, February 13, 2024
Sodium chloride, DEHP, PVC, Patient, Pain management, Medical device

BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.

Key Points: 
  • BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.
  • This new addition to the portfolio enhances the Company's ability to serve the diverse needs of healthcare facilities and their patients for this high-alert medication.
  • The B. Braun Heparin portfolio is manufactured using EXCEL® IV Containers which are not made with natural rubber latex, DEHP or PVC, placing a priority on patient and environmental safety.
  • Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.

Preterm Births Linked to 'Hormone Disruptor' Chemicals May Cost United States Billions

Retrieved on: 
Tuesday, February 6, 2024
ECHO, University, Columbia University, NYU, Cosmetics, Phthalate, Bangladesh Technical Education Board, Champaign–Urbana metropolitan area, Wayne State University, Lancet, NYU Langone Health, Food, National Institutes of Health, DEHP, MPH, Emory University, Woman, Johns Hopkins University, Population health, MPP, Blood, DIDP, Northeastern University, Infant, Risk, Doctor of Philosophy, Rutgers University, Cancer, Gestational age, Triangle Park (Quezon City), Racism, Mother, Research, Obesity, Preterm birth, RTI International, The Lancet, Pregnancy, Doctor of Science, Dartmouth College, Diabetes, Pennsylvania State University, Urine, Hormone, Achievement Medal, Pediatrics, Dietary supplement

Then, the team looked for associations between these metabolite levels and preterm births.

Key Points: 
  • Then, the team looked for associations between these metabolite levels and preterm births.
  • "Otherwise, investigators are likely going to find the same study results in another few years about the next group of chemicals used as replacements."
  • California, among a few states, has banned some use of phthalates in consumer products, as have European Union member states.
  • Trasande cautions that further research is needed to better understand the specific mechanisms behind the link between phthalate exposure and preterm birth.

BetterCaths Coalition Assists Rep. Josh Turek in Designing Better Caths for Iowa Act to Remove Harmful Phthalate Chemical DEHP From Urological Catheters

Retrieved on: 
Sunday, February 26, 2023
Allergy, Parkinson's disease, SCI/D, Cauda equina, Catheter, Learning, Cancer, Patient, Tokyo, Prostate cancer, Mortality, Iowa House of Representatives, Medicaid, Survivor, Organization, National Transportation Safety Board, Transverse myelitis, Bladder cancer, Health equity, Spina bifida, PVC, Norfolk Southern Railway, Legislation, Dementia, Cardiac catheterization, DEHP, Vinyl chloride, Human, Disability, Polyvinyl chloride, Australian Transport Safety Bureau, United Spinal Association, Asthma, Insulin resistance, Multiple sclerosis, Phthalate, Stroke, Urinary catheterization, Language, Medical device, Pharmaceutical industry, Dietary supplement, Medical imaging, Tokyo Paralympics

The Better Caths for Iowa Act is the first piece of legislation in the country that aims to lower the bladder cancer mortality rate for people whose lives depend on using urological catheters.

Key Points: 
  • The Better Caths for Iowa Act is the first piece of legislation in the country that aims to lower the bladder cancer mortality rate for people whose lives depend on using urological catheters.
  • It also protects Iowa Medicaid patients from daily exposure to the toxic chemical (DEHP) in some commonly-used urinary catheters.
  • The BetterCaths for Iowa Act places an immediate ban on Iowa Medicaid reimbursement of catheters that have known carcinogen warning labels.
  • It also requires Iowa Medicaid to review the historical bladder cancer rate and correlating brands of catheters used by their patients.

Dimensional Lists Three New Emerging Markets Equity ETFs

Retrieved on: 
Wednesday, April 27, 2022
Professional Services, Finance, New, Market loss payments, Bangladesh Securities and Exchange Commission, Security (finance), Research, AUM, ETF, Dimensional Fund Advisors, DFEM, Depreciation, Sale, Prospectus, Spinal muscular atrophies, Solution, DEHP, NYSE, Risk, Financial adviser, Financial services, Dimension

Dimensional Fund Advisors, a global leader in systematic investing, expanded its exchange-traded funds (ETFs) offering with todays listing of three emerging markets equity ETFs, which offer broadly diversified exposure to core, value, and high profitability1 equities within emerging markets.

Key Points: 
  • Dimensional Fund Advisors, a global leader in systematic investing, expanded its exchange-traded funds (ETFs) offering with todays listing of three emerging markets equity ETFs, which offer broadly diversified exposure to core, value, and high profitability1 equities within emerging markets.
  • Investors can benefit from these funds broadly diversified exposure to emerging markets, delivered with a robust, systematic, and scalable pursuit of higher expected returns.
  • Our expanding ETF suite provides financial professionals with a full set of solutions to build globally diversified asset allocation models using Dimensional ETFs, said Co-CEO Dave Butler.
  • 2 Dimensional has agreed to waive certain fees and, in certain instances, assume certain expenses of the ETFs.

Vertellus To Present Industry-Leading Portfolio of Medical Adhesives and Coatings at MD&M West 2022

Retrieved on: 
Wednesday, March 30, 2022
Cardiology, Biotechnology, Other Manufacturing, Health, Medical Devices, Chemicals, Plastics, Manufacturing, Other Health, Booth, European Pharmacopoeia, Medicine, PVC, DEHP, Thrombosis, Compliance, Hardness, Cardiology, Urology, Oxygenator, Health, B6, Quality of life, Anaheim Convention Center, Industry, Technology, REACH, Chip PC Technologies, Rheology, Chemistry, Solution, Catheter, Partnership, Medical device

Vertellus industry leading portfolio of Biothane systems include its Polycin polyols and Vorite prepolymer components.

Key Points: 
  • Vertellus industry leading portfolio of Biothane systems include its Polycin polyols and Vorite prepolymer components.
  • Vertellus invites customers and visitors to experience its Citroflex B6, Biothane and PC Technology solutions in Booth 1289.
  • Vertellus technology can be found in personal care products, pharmaceuticals, medical devices, nutraceuticals, food & beverages, performance coatings, transportation additives and more.
  • Headquartered in Indianapolis and founded in 1857, Vertellus has more than 1,300 employees across 15 international research and manufacturing facilities.

B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site

Retrieved on: 
Friday, January 28, 2022
CEO, Patient, B. Braun, Health, Dialysis, Sodium chloride, Company, Pain management, COVID-19, PVC, DEHP, Injection, Senior, FDA, IV, Multimedia, Solution, CA, Pharmaceutical industry

BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL.

Key Points: 
  • BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL.
  • The new Daytona Beach facility is part of B. Braun's commitment to invest over $1 billion dollars to alleviate IV fluid shortages by creating additional supply and manufacturing capacity in the United States.
  • "FDA approval of our state-of-the-art pharmaceutical manufacturing plant in Daytona Beach is a win for patients across the United States," said Jean-Claude Dubacher, Chairman and CEO of B. Braun of America.
  • B. Braun Medical is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculapand CAPS.

Government of Canada announces the release of the latest results from the Canadian Health Measures Survey

Retrieved on: 
Tuesday, December 14, 2021
Health Canada, Public Health Agency of Canada, City, Life, Public Health Agency, CHMS, DEHP, Toxicity, Environment, Time, Research, Safety, Statistics Canada, Collection, Policy, Blood, Student, Partnership, The Honourable, Dietary supplement, Oil, Environmental remediation, Health

The biomonitoring component of the Canadian Health Measures Survey (CHMS) collects meaningful data that informs evidence-based decisions to protect the health and safety of Canadians.

Key Points: 
  • The biomonitoring component of the Canadian Health Measures Survey (CHMS) collects meaningful data that informs evidence-based decisions to protect the health and safety of Canadians.
  • Today, the Honourable Jean-Yves Duclos, Minister of Health, announces the release of the Sixth Report on Human Biomonitoring of Environmental Chemicals in Canada featuring recent results from the Canadian Health Measures Survey (CHMS) cycle 6 (20182019).
  • The most recent results, paired with results from previous cycles of the CHMS, allow us to report on trends in chemical exposure over time.
  • The CHMS is led by Statistics Canada in partnership with Health Canada and the Public Health Agency of Canada.

B. Braun Announces Nationwide Availability of Magnesium Sulfate Family of Products

Retrieved on: 
Wednesday, December 8, 2021
Infant, Central nervous system, Magnesium sulfate, PAB, B. Braun, Risk, Pregnancy, Contraindication, Medical Affairs Bureau, PVC, Therapy, Pain management, Dialysis, CAPS, Woman, USP, Toxemia, Death, Convulsion, Liver, Platelet, Patient, Thornburgh v. American College of Obstetricians & Gynecologists, Corporation, Urine, American College, Company, Eclampsia, Myasthenia gravis, Foundation, Approximation error, Glucose, DEHP, Multimedia, ACOG, Lists of diseases, Treatment, Heart block, Pharmacist, Diabetic coma, Preterm birth, Gynaecology, Mother, Seizure, Medical device, Birth control, Aluminium, Pharmaceutical industry, Television

Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it."

Key Points: 
  • Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it."
  • Someof the many characteristics of B. Braun's Magnesium Sulfate products include:
    Domestically manufactured and sourced: In addition to being manufactured in Irvine, California, B. Braun's Magnesium Sulfate products are produced with American-made active pharmaceutical ingredients, helping ensure consistent supply levels.
  • Eco-friendly Packaging: B. Braun's Magnesium Sulfate products do not require an overwrap like other ready-to-use Magnesium Sulfate pre-mixed bags, reducing landfill waste.
  • Ready-to-Use Pre-Mixed Bags: Doses include Magnesium Sulfate in 5% Dextrose, 1 g/100 mL, Magnesium Sulfate in Water, 2 g/50 mL, Magnesium Sulfate in Water, 4 g/50 mL, and Magnesium Sulfate in Water, 4 g/100 mL.

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

Retrieved on: 
Thursday, November 4, 2021
Safety, Anemia, Plasticizer, History, EUR, Commercial Operating System (COS), MCE, Multimedia, Health, GRF, ADR, Allergy, PVC, Coagulation, Blood, Transfusion medicine, Ovarian hyperstimulation syndrome, Creutzfeldt–Jakob disease, Hematology, Food, Water, Regulation of tobacco by the U.S. Food and Drug Administration, Respiratory distress syndrome, S.A, Solution, Plasmapheresis, Pharmacy, Hospital, Excipient, Red blood cell, Carbon, Dehydration, Hypersensitivity, CJD, Hypovolemia, Phthalate, Sale, Legislation, Heart failure, Patient, Heart, Plasma, Hemolysis, Anaphylaxis, Pulmonary edema, Paracentesis, Hypervolemia, NASDAQ, FDA, Electrolyte, Adult, Polyvinyl chloride, DEHP, Blood product, Medical device, Birth control

"This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."

Key Points: 
  • "This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."
  • Sustainability was key for Grifols when developing the environmentally friendly ALBUTEIN FlexBag.
  • Both the ALBUTEIN FlexBag flexible container and protective overwrap are latex-free and do not contain polyvinyl chloride (PVC), diethylhexyl phthalate (DEHP) or other plasticizers.
  • The launch of ALBUTEIN FlexBag solidifies Grifols commitment to R+D+i, which has enabled the company to further expand its industry-leading portfolio of plasma-derived medicines for patients and healthcare professionals.

B. Braun Launches CARESAFE™ IV Administration Sets With Optional AirStop

Retrieved on: 
Tuesday, September 21, 2021
Adoption, EDC, Centers for Medicare & Medicaid Services, Dioxin, Running, Phthalate, Pain management, Polyvinyl chloride, Vascular access, B. Braun, Medicare, American Medical Association, Patient, CMS, PVC, Atmosphere, Physician, Public health insurance option, Dialysis, Company, Hospital, Environment, Center, Risk, DEHP, Incineration, Male, APG IV system, United States National Library of Medicine, Pregnancy, Safety, Diagnosis, Multimedia, Medical device, Pharmaceutical industry, Thermoplastic

BETHLEHEM, Pa., Sept. 21, 2021 /PRNewswire/ --B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today the launch of its new CARESAFE IV Administration Sets with Optional AirStop component.

Key Points: 
  • BETHLEHEM, Pa., Sept. 21, 2021 /PRNewswire/ --B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today the launch of its new CARESAFE IV Administration Sets with Optional AirStop component.
  • CARESAFE IV Sets are the first robust portfolio of IV administration sets in the US market that are not made with polyvinyl chloride (PVC) and diethylhexyl phthalate (DEHP).
  • [4]
    In addition to reducing patient exposure to toxic substances, CARESAFE IV Sets with Optional AirStop component also help to protect patients from the risks associated with air infusion and helps prevent the line from running dry.
  • B. Braun Medical is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculapand CAPS.